AEGiS-FDA: Link for CCR5 co-receptor meeting webcast Food and Drug AdministrationImportant note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


Link for CCR5 co-receptor meeting webcast

Food and Drug Administration - May 30, 2006
Richard Klein, HIV/AIDS Program Director


Apparently some people have had problems with the link to the CCR5 meeting webcast page. The purpose of the meeting is to discuss issues regarding the development of CCR5 co-receptor antagonists for the treatment of HIV infection

Please use http://www.hivforum.org/CCR5/webcast.html if you experienced a problem accessing the link.

For questions about the May 31 meeting, please contact Becky Griesse at blg@gwu.edu or at 202-416-0494.

Richard Klein HIV/AIDS Program Director Office of Special Health Issues Food and Drug Administration


060530
FD060505


SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .